Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership decreased its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 2.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,893,681 shares of the company’s stock after selling 125,185 shares during the quarter. Artisan Partners Limited Partnership owned about 0.10% of Twist Bioscience worth $273,879,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Arizona State Retirement System raised its stake in shares of Twist Bioscience by 1.3% in the 4th quarter. Arizona State Retirement System now owns 16,985 shares of the company’s stock valued at $789,000 after acquiring an additional 219 shares during the period. Van ECK Associates Corp boosted its position in shares of Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after purchasing an additional 267 shares during the period. Hillsdale Investment Management Inc. increased its holdings in Twist Bioscience by 0.4% in the 4th quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company’s stock valued at $3,625,000 after purchasing an additional 300 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Twist Bioscience by 2.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock valued at $734,000 after purchasing an additional 363 shares during the period. Finally, US Bancorp DE lifted its stake in Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after purchasing an additional 601 shares in the last quarter.

Insider Buying and Selling at Twist Bioscience

In other news, SVP Paula Green sold 1,259 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $62,131.65. Following the completion of the sale, the senior vice president now directly owns 132,014 shares of the company’s stock, valued at approximately $6,514,890.90. This represents a 0.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert Chess sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $50.00, for a total transaction of $250,000.00. Following the transaction, the director now owns 16,641 shares in the company, valued at approximately $832,050. This trade represents a 23.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,799 shares of company stock worth $1,593,944 over the last 90 days. Corporate insiders own 3.01% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on TWST shares. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Robert W. Baird boosted their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. JPMorgan Chase & Co. raised their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research note on Tuesday, February 4th. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Finally, Wolfe Research initiated coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $54.40.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $41.88 on Thursday. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The company has a fifty day simple moving average of $45.38 and a 200-day simple moving average of $45.34. The stock has a market cap of $2.50 billion, a P/E ratio of -12.39 and a beta of 2.15. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same period in the previous year, the business earned ($0.75) EPS. Twist Bioscience’s revenue for the quarter was up 24.1% on a year-over-year basis. Equities analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.